extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents
parent
29a7e87561
commit
130d48f31c
6 changed files with 61 additions and 1 deletions
|
|
@ -47,6 +47,12 @@ MASH/NASH is projected to become the leading cause of liver transplantation. GLP
|
|||
|
||||
The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
Medicare-specific modeling shows net savings of $715M over 10 years when multi-indication benefits (T2D, obesity, MASH) are comprehensively accounted for. The T2D-related savings alone ($892M) exceed obesity-related costs ($205M). This suggests the 'inflationary through 2035' framing applies to system-level economics where costs and savings are distributed, but not necessarily to risk-bearing payers who capture both sides of the equation.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -21,6 +21,12 @@ The competitive landscape for value-based care is consolidating around four stru
|
|||
|
||||
These four organizations plus subsidiaries comprised 70% of terminated MA plan members in 2025, indicating consolidation among winners. The structural question is whether acquisition-based vertical integration's market share advantage survives growing regulatory pressure (CMS chart review exclusion, antitrust enforcement, MLR scrutiny), or whether purpose-built and aligned models prove more durable at comparable outcomes.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
The divergence between Medicare-level savings ($715M over 10 years) and system-level inflationary impact provides empirical evidence for why vertical integration and risk-bearing arrangements matter. When a single entity captures both drug costs and downstream savings, GLP-1s become cost-effective. When costs and savings are distributed across multiple payers and time periods, the economics remain inflationary. This is a concrete example of how payment model structure determines whether prevention investments generate positive ROI.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -48,6 +48,12 @@ Phase 3 trial shows semaglutide 2.4mg achieves 62.9% resolution of steatohepatit
|
|||
|
||||
FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0.56-0.89) and 18% lower risk of major cardiovascular events in a kidney-focused trial. The cardiovascular benefits emerged as secondary endpoints in a study designed for kidney outcomes, supporting the multi-organ protection thesis. Separate analysis in Nature Medicine showed additive benefits when combined with SGLT2 inhibitors.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
Medicare modeling quantifies the multi-organ benefit: per 100,000 subjects treated, semaglutide avoids 2,791 non-fatal MIs, 3,000 coronary revascularizations, 487 non-fatal strokes, and 115 CV deaths. Per-subject savings break down as $14,431 from avoided T2D, $2,074 from avoided CKD, and $1,512 from avoided CV events, demonstrating that the compounding value is measurable and substantial enough to offset drug costs under the right payment structure.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -34,6 +34,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist,
|
|||
|
||||
FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major kidney disease events (HR 0.76, P=0.0003), with annual eGFR decline slowed by 1.16 mL/min/1.73m2 (P<0.001). Trial stopped early at prespecified interim analysis due to efficacy. FDA subsequently expanded semaglutide indications to include T2D patients with CKD. This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, published in NEJM.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-16*
|
||||
|
||||
The Medicare modeling confirms CKD savings of $2,074 per subject over lifetime treatment, supporting the claim that kidney disease progression delay creates substantial per-patient cost offsets. While smaller than T2D savings ($14,431/subject), the CKD benefit is a significant component of the multi-indication value proposition.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,24 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 1,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md:set_created:2026-03-16"
|
||||
],
|
||||
"rejections": [
|
||||
"comprehensive-glp-1-access-saves-medicare-money-when-single-payer-captures-multi-indication-benefits.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-16"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2025-06-01
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: paper
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-16
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -39,3 +43,11 @@ Key findings:
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: This study provides the strongest evidence that the "inflationary through 2035" framing needs scope qualification — system-level vs. payer-level economics diverge when downstream savings accrue to the same entity
|
||||
EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Medicare semaglutide modeling projects 38,950 cardiovascular events avoided over 10 years (2026-2035)
|
||||
- Medicare semaglutide modeling projects 6,180 deaths avoided over 10 years
|
||||
- Average per-subject lifetime semaglutide treatment costs: $47,353
|
||||
- Per 100,000 subjects treated: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided
|
||||
- MASH-related savings are only $28M over 10 years despite impressive clinical data, suggesting MASH treatment costs don't accumulate enough in the 10-year window to produce large offsets
|
||||
|
|
|
|||
Loading…
Reference in a new issue